![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Purdue Pharma Discovery Research, Cranbury, New Jersey
The vanilloid receptor 1 (VR1) is a cation channel expressed predominantly by nociceptive sensory neurons and is activated by a wide array of pain-producing stimuli, including capsaicin, noxious heat, and low pH. Although the behavioral effects of injected capsaicin and the VR1 antagonist capsazepine have indicated a potential role for VR1 in the generation and maintenance of persistent pain states, species differences in the molecular pharmacology of VR1 and a limited number of selective ligands have made VR1 difficult to study in vivo. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropryazine-1(2H)-carbox-amide (BCTC) is a recently described inhibitor of capsaicin- and acid-mediated currents at rat VR1. Here, we report the effects of BCTC on acute, inflammatory, and neuropathic pain in rats. Administration of BCTC (30 mg/kg p.o.) significantly reduced both mechanical and thermal hyperalgesia induced by intraplantar injection of 30 µg of capsaicin. In rats with Freund's complete adjuvantinduced inflammation, BCTC significantly reduced the accompanying thermal and mechanical hyperalgesia (3 mg/kg and 10 mg/kg p.o., respectively). BCTC also reduced mechanical hyperalgesia and tactile allodynia 2 weeks after partial sciatic nerve injury (10 and 30 mg/kg p.o.). BCTC did not affect motor performance on the rotarod after administration of doses up to 50 mg/kg p.o. These data suggest a role for VR1 in persistent and chronic pain arising from inflammation or nerve injury.
Address correspondence to: Kenneth J. Valenzano, 6 Cedarbrook Dr., Cranbury, NJ 08512. E-mail: ken.valenzano{at}pharma.com
This article has been cited by other articles:
|
|
 |
|
  J. Vriens, G. Appendino, and B. Nilius Pharmacology of Vanilloid Transient Receptor Potential Cation Channels Mol. Pharmacol., June 1, 2009; 75(6): 1262 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ohta, T. Imagawa, and S. Ito Involvement of Transient Receptor Potential Vanilloid Subtype 1 in Analgesic Action of Methylsalicylate Mol. Pharmacol., February 1, 2009; 75(2): 307 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. McGaraughty, K. L. Chu, B. S. Brown, C. Z. Zhu, C. Zhong, S. K. Joshi, P. Honore, C. R. Faltynek, and M. F. Jarvis Contributions of Central and Peripheral TRPV1 Receptors to Mechanically Evoked and Spontaneous Firing of Spinal Neurons in Inflamed Rats J Neurophysiol, December 1, 2008; 100(6): 3158 - 3166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Escalera, C. A. von Hehn, B. F. Bessac, M. Sivula, and S.-E. Jordt TRPA1 Mediates the Noxious Effects of Natural Sesquiterpene Deterrents J. Biol. Chem., August 29, 2008; 283(35): 24136 - 24144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Vetter, W. Cheng, M. Peiris, B. D. Wyse, S. J. Roberts-Thomson, J. Zheng, G. R. Monteith, and P. J. Cabot Rapid, Opioid-sensitive Mechanisms Involved in Transient Receptor Potential Vanilloid 1 Sensitization J. Biol. Chem., July 11, 2008; 283(28): 19540 - 19550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Lehto, R. Tamir, H. Deng, L. Klionsky, R. Kuang, A. Le, D. Lee, J.-C. Louis, E. Magal, B. H. Manning, et al. Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 218 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ohta, T. Imagawa, and S. Ito Novel Gating and Sensitizing Mechanism of Capsaicin Receptor (TRPV1): TONIC INHIBITORY REGULATION OF EXTRACELLULAR SODIUM THROUGH THE EXTERNAL PROTONATION SITES ON TRPV1 J. Biol. Chem., April 4, 2008; 283(14): 9377 - 9387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. U. De Schepper, J. G. De Man, N. E. Ruyssers, A. Deiteren, L. Van Nassauw, J.-P. Timmermans, W. Martinet, A. G. Herman, P. A. Pelckmans, and B. Y. De Winter TRPV1 receptor signaling mediates afferent nerve sensitization during colitis-induced motility disorders in rats Am J Physiol Gastrointest Liver Physiol, January 1, 2008; 294(1): G245 - G253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Gavva, A. W. Bannon, D. N. Hovland Jr., S. G. Lehto, L. Klionsky, S. Surapaneni, D. C. Immke, C. Henley, L. Arik, A. Bak, et al. Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Gunthorpe, S. L. Hannan, D. Smart, J. C. Jerman, S. Arpino, G. D. Smith, S. Brough, J. Wright, J. Egerton, S. C. Lappin, et al. Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid-, and Heat-Mediated Activation of the Receptor J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1183 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tang, Y. Chen, Z. Chen, P. M. Blumberg, A. P. Kozikowski, and Z. J. Wang Antinociceptive Pharmacology of N-(4-Chlorobenzyl)-N'-(4-hydroxy-3-iodo-5-methoxybenzyl) Thiourea, a High-Affinity Competitive Antagonist of the Transient Receptor Potential Vanilloid 1 Receptor J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 791 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kissin, C. F. Freitas, and E. L. Bradley Jr Perineural Resiniferatoxin Prevents the Development of Hyperalgesia Produced by Loose Ligation of the Sciatic Nerve in Rats Anesth. Analg., May 1, 2007; 104(5): 1210 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Liedtke Hydromineral Neuroendocrinology: Role of TRPV ion channels in sensory transduction of osmotic stimuli in mammals Exp Physiol, May 1, 2007; 92(3): 507 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Gavva, A. W. Bannon, S. Surapaneni, D. N. Hovland Jr, S. G. Lehto, A. Gore, T. Juan, H. Deng, B. Han, L. Klionsky, et al. The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation J. Neurosci., March 28, 2007; 27(13): 3366 - 3374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Liedtke Transient receptor potential vanilloid channels functioning in transduction of osmotic stimuli J. Endocrinol., December 1, 2006; 191(3): 515 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cui, P. Honore, C. Zhong, D. Gauvin, J. Mikusa, G. Hernandez, P. Chandran, A. Gomtsyan, B. Brown, E. K. Bayburt, et al. TRPV1 Receptors in the CNS Play a Key Role in Broad-Spectrum Analgesia of TRPV1 Antagonists. J. Neurosci., September 13, 2006; 26(37): 9385 - 9393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Gavva, R. Tamir, L. Klionsky, M. H. Norman, J.-C. Louis, K. D. Wild, and J. J. S. Treanor Proton Activation Does Not Alter Antagonist Interaction with the Capsaicin-Binding Pocket of TRPV1 Mol. Pharmacol., December 1, 2005; 68(6): 1524 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Hogestatt, B. A. G. Jonsson, A. Ermund, D. A. Andersson, H. Bjork, J. P. Alexander, B. F. Cravatt, A. I. Basbaum, and P. M. Zygmunt Conversion of Acetaminophen to the Bioactive N-Acylphenolamine AM404 via Fatty Acid Amide Hydrolase-dependent Arachidonic Acid Conjugation in the Nervous System J. Biol. Chem., September 9, 2005; 280(36): 31405 - 31412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Honore, C. T. Wismer, J. Mikusa, C. Z. Zhu, C. Zhong, D. M. Gauvin, A. Gomtsyan, R. El Kouhen, C.-H. Lee, K. Marsh, et al. A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 410 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Gavva, R. Tamir, Y. Qu, L. Klionsky, T. J. Zhang, D. Immke, J. Wang, D. Zhu, T. W. Vanderah, F. Porreca, et al. AMG 9810 [(E)-3-(4-t-Butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a Novel Vanilloid Receptor 1 (TRPV1) Antagonist with Antihyperalgesic Properties J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 474 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Rong, K. Hillsley, J. B Davis, G. Hicks, W. J Winchester, and D. Grundy Jejunal afferent nerve sensitivity in wild-type and TRPV1 knockout mice J. Physiol., November 1, 2004; 560(3): 867 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Gavva, L. Klionsky, Y. Qu, L. Shi, R. Tamir, S. Edenson, T. J. Zhang, V. N. Viswanadhan, A. Toth, L. V. Pearce, et al. Molecular Determinants of Vanilloid Sensitivity in TRPV1 J. Biol. Chem., May 7, 2004; 279(19): 20283 - 20295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Toth, P. M. Blumberg, Z. Chen, and A. P. Kozikowski Design of a High-Affinity Competitive Antagonist of the Vanilloid Receptor Selective for the Calcium Entry-Linked Receptor Population Mol. Pharmacol., February 1, 2004; 65(2): 282 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Valenzano, E. R. Grant, G. Wu, M. Hachicha, L. Schmid, L. Tafesse, Q. Sun, Y. Rotshteyn, J. Francis, J. Limberis, et al. N-(4-Tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: I. In Vitro Characterization and Pharmacokinetic Properties J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 377 - 386. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
